Results 201 to 210 of about 128,354 (367)

Mortalin and PINK1/Parkin‐Mediated Mitophagy Represent Ovarian Cancer‐Selective Targets for Drug Development

open access: yesAdvanced Science, EarlyView.
Ovarian cancer patients with high levels of mortalin protein in their tumors have worse survival. The investigational drug SHetA2 interferes with mortalin's support of mitochondria. The resulting mitochondrial damage causes a process called mitophagy that contributes to how SHetA2 kills cancer cells. Noncancerous cells repair their mitochondria through
Vishal Chandra   +9 more
wiley   +1 more source

Post‐Translational Modifications of TOE3 Regulate Antiviral Defense in Tobacco

open access: yesAdvanced Science, EarlyView.
CK2αL phosphorylates TOE3 and enhances its stability, while FBXL1 promotes the ubiquitination‐degradation of TOE3 via the 26S proteasome. Compared to CK2αL‐phosphorylated TOE3, nonphosphorylated TOE3 shows a much higher affinity for FBXL1 and is more susceptible to ubiquitination‐degradation, thus facilitating viral infection. The regulatory mechanisms
Bolei Jiao   +3 more
wiley   +1 more source

Elastase-alpha1-proteinase inhibitor complex [PDF]

open access: yes, 1984
Bergmeyer, H. U.   +4 more
core   +1 more source

A Study of Skeletal Stem Cell Dynamics and Its Potential Applications in the Design of a Titanium Implant for Senile Osteoporosis

open access: yesAdvanced Science, EarlyView.
Senescent mesenchymal stromal cells (MSCs) drive age‐related osteoporosis (A‐OP) via adipogenic bias. Resveratrol, selected from transcriptome‐identified core genes, is delivered locally using GelMA‐chitosan hydrogel‐functionalised titanium implants. In A‐OP microenvironments, the hydrogel enables the sustained release of resveratrol, which reverses ...
Wuzhe Fan   +12 more
wiley   +1 more source

AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists

open access: yesAdvanced Science, EarlyView.
De novo GLP‐1RAs can be computationally designed to exhibit extended half‐life and superior efficacy compared to Semaglutide. Abstract Peptide drugs have revolutionized modern therapeutics, offering novel treatment avenues for various diseases. Nevertheless, low design efficacy, time consumption, and high cost still hinder peptide drug design and ...
Ting Wei   +13 more
wiley   +1 more source

S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs. [PDF]

open access: yesCancer Res, 2012
Grek CL   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy